SA520420382B1 - مُعدِّلات تفارغية موجبة تجاه مستقبل دوبامين 1 - Google Patents
مُعدِّلات تفارغية موجبة تجاه مستقبل دوبامين 1Info
- Publication number
- SA520420382B1 SA520420382B1 SA520420382A SA520420382A SA520420382B1 SA 520420382 B1 SA520420382 B1 SA 520420382B1 SA 520420382 A SA520420382 A SA 520420382A SA 520420382 A SA520420382 A SA 520420382A SA 520420382 B1 SA520420382 B1 SA 520420382B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- positive allosteric
- allosteric modulators
- dopamine
- receptor positive
- disease
- Prior art date
Links
- 230000003281 allosteric effect Effects 0.000 title abstract 2
- 102000004076 Dopamine D1 Receptors Human genes 0.000 title 1
- 108090000511 Dopamine D1 Receptors Proteins 0.000 title 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical class CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
يتعلّق الاختراع الحالي بمركبات (فينيل)-(بيرازول)-3، 4-داي هيدرو أيزو كينولين-2(1H)-يل)إيثان-1-ون (phenyl)-(pyrazol)-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one compounds معينة لها الصيغة I كمعدلات تفارغية موجبة positive allosteric modulators (PAMs) تجاه دوبامين 1 dopamine 1 (D1)، وتركيبات صيدلية pharmaceutical compositions منها. يوفر الاختراع كذلك طرق استخدام مركب له الصيغة I، أو ملح مقبول صيدليًا pharmaceutically acceptable salt منه، لعلاج أعراض معينة لمرض باركنسون Parkinson's disease، الشيزوفرانيا schizophrenia، اضطراب نقص الانتباه مع فرط النشاط Attention deficit hyperactivity disorder (ADHD) أو مرض آلزهيمار Alzheimer's disease. (I)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862660622P | 2018-04-20 | 2018-04-20 | |
| PCT/US2019/027842 WO2019204418A1 (en) | 2018-04-20 | 2019-04-17 | Pyrazo-tetrahydroisoquinoline derivatives as dopamine d1 receptor positive modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA520420382B1 true SA520420382B1 (ar) | 2022-08-04 |
Family
ID=66324031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA520420382A SA520420382B1 (ar) | 2018-04-20 | 2020-10-19 | مُعدِّلات تفارغية موجبة تجاه مستقبل دوبامين 1 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10611751B2 (ar) |
| EP (1) | EP3781560B1 (ar) |
| JP (1) | JP7083916B2 (ar) |
| KR (1) | KR102520872B1 (ar) |
| CN (1) | CN111971282B (ar) |
| AR (1) | AR114467A1 (ar) |
| AU (1) | AU2019256350B2 (ar) |
| BR (1) | BR112020019934A2 (ar) |
| CA (1) | CA3097692C (ar) |
| CL (1) | CL2020002697A1 (ar) |
| CO (1) | CO2020012678A2 (ar) |
| CR (1) | CR20200481A (ar) |
| EA (1) | EA202092146A1 (ar) |
| EC (1) | ECSP20066271A (ar) |
| ES (1) | ES2927142T3 (ar) |
| IL (1) | IL278045B2 (ar) |
| JO (1) | JOP20200263A1 (ar) |
| MA (1) | MA52286A (ar) |
| MX (1) | MX2020010914A (ar) |
| MY (1) | MY197645A (ar) |
| NZ (1) | NZ767900A (ar) |
| PE (1) | PE20201151A1 (ar) |
| PH (1) | PH12020551713A1 (ar) |
| SA (1) | SA520420382B1 (ar) |
| SG (1) | SG11202009938TA (ar) |
| TW (1) | TWI725408B (ar) |
| UA (1) | UA125271C2 (ar) |
| WO (1) | WO2019204418A1 (ar) |
| ZA (1) | ZA202006439B (ar) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3993794A1 (en) | 2019-07-01 | 2022-05-11 | UCB Biopharma SRL | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
| CA3139622A1 (en) | 2019-07-01 | 2021-01-07 | UCB Biopharma SRL | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
| US20240083875A1 (en) | 2020-12-18 | 2024-03-14 | UCB Biopharma SRL | Dihydroisoquinolinyl derivatives |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE68910999T2 (de) | 1988-02-19 | 1994-03-24 | Smithkline Beecham Farma | 1,2,3,4-Tetrahydroisoquinoline, Verfharen zu ihrer Herstellung und ihre Verwendung als Kappa-Rezeptor Agonisten. |
| US5236934A (en) | 1992-08-26 | 1993-08-17 | E. I. Du Pont De Nemours And Company | 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders |
| WO2001085695A1 (en) | 2000-05-11 | 2001-11-15 | Bristol-Myers Squibb Co. | Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
| US7601739B2 (en) | 2003-08-08 | 2009-10-13 | Virgina Commonwealth University | Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases |
| AR095883A1 (es) | 2013-04-18 | 2015-11-18 | Astellas Pharma Inc | Compuestos de acetamida heterocíclica |
| JO3316B1 (ar) * | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| CA2963951C (en) * | 2014-10-08 | 2023-02-28 | Ucb Biopharma Sprl | Tetrahydroisoquinoline derivatives |
| EP3204374B1 (en) | 2014-10-08 | 2019-04-03 | UCB Biopharma SPRL | Isoindoline derivatives |
| AR105025A1 (es) | 2015-06-19 | 2017-08-30 | Astellas Pharma Inc | Compuesto de imidazodiazepina |
| AR106332A1 (es) * | 2015-10-23 | 2018-01-03 | Lilly Co Eli | Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona |
| EP3442945B1 (en) | 2016-04-13 | 2020-07-08 | UCB Biopharma SRL | Tetrahydroisoquinoline derivatives |
| EP3418270A1 (en) | 2017-06-19 | 2018-12-26 | Universidad Complutense De Madrid | Novel biphenylsulfoximines as allosteric modulators of the dopamine d1 receptor |
| WO2019173437A1 (en) | 2018-03-06 | 2019-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Positive allosteric modulators of dopamine 1 receptor and method of use thereof |
-
2019
- 2019-04-03 TW TW108111844A patent/TWI725408B/zh active
- 2019-04-04 AR ARP190100882A patent/AR114467A1/es unknown
- 2019-04-17 JP JP2020557950A patent/JP7083916B2/ja active Active
- 2019-04-17 SG SG11202009938TA patent/SG11202009938TA/en unknown
- 2019-04-17 KR KR1020207029608A patent/KR102520872B1/ko active IP Right Grant
- 2019-04-17 UA UAA202005900A patent/UA125271C2/uk unknown
- 2019-04-17 IL IL278045A patent/IL278045B2/en unknown
- 2019-04-17 BR BR112020019934-6A patent/BR112020019934A2/pt unknown
- 2019-04-17 CN CN201980027079.8A patent/CN111971282B/zh active Active
- 2019-04-17 US US16/386,684 patent/US10611751B2/en active Active
- 2019-04-17 PE PE2020001478A patent/PE20201151A1/es unknown
- 2019-04-17 ES ES19720352T patent/ES2927142T3/es active Active
- 2019-04-17 JO JOP/2020/0263A patent/JOP20200263A1/ar unknown
- 2019-04-17 CA CA3097692A patent/CA3097692C/en active Active
- 2019-04-17 MY MYPI2020005419A patent/MY197645A/en unknown
- 2019-04-17 MA MA052286A patent/MA52286A/fr unknown
- 2019-04-17 CR CR20200481A patent/CR20200481A/es unknown
- 2019-04-17 WO PCT/US2019/027842 patent/WO2019204418A1/en active Application Filing
- 2019-04-17 NZ NZ767900A patent/NZ767900A/en unknown
- 2019-04-17 MX MX2020010914A patent/MX2020010914A/es unknown
- 2019-04-17 EP EP19720352.4A patent/EP3781560B1/en active Active
- 2019-04-17 AU AU2019256350A patent/AU2019256350B2/en active Active
- 2019-04-17 EA EA202092146A patent/EA202092146A1/ru unknown
-
2020
- 2020-10-09 PH PH12020551713A patent/PH12020551713A1/en unknown
- 2020-10-13 CO CONC2020/0012678A patent/CO2020012678A2/es unknown
- 2020-10-16 ZA ZA2020/06439A patent/ZA202006439B/en unknown
- 2020-10-16 CL CL2020002697A patent/CL2020002697A1/es unknown
- 2020-10-19 SA SA520420382A patent/SA520420382B1/ar unknown
- 2020-10-19 EC ECSENADI202066271A patent/ECSP20066271A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020005363A (es) | Compuestos heterociclicos como inhibidores de prmt5. | |
| MA41134B1 (fr) | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales | |
| PH12016501440A1 (en) | Novel heterocyclic compounds | |
| SA520420382B1 (ar) | مُعدِّلات تفارغية موجبة تجاه مستقبل دوبامين 1 | |
| PH12020550881A1 (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
| MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
| MX2019002180A (es) | Moduladores alostericos positivos del receptor m1 muscarinico. | |
| MA42339A1 (fr) | Modulateurs du récepteur farnésoïde x | |
| PH12015502658A1 (en) | 3,4-dihydroisoquinolin-2 (1h)-yl compounds | |
| PH12020552092A1 (en) | Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease | |
| NZ721645A (en) | Compounds for use as gpr120 agonists | |
| MX2021011118A (es) | Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2. | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| MA41633B1 (fr) | Composés amide en tant qu'agonistes du récepteur 5-ht4 | |
| NZ746906A (en) | Oxaborole esters and uses thereof | |
| MX2020007985A (es) | Inhibicion del canal ionico receptor de potencial transitorio a1. | |
| MY195576A (en) | Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof | |
| MX2020008523A (es) | Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5). | |
| JOP20220084A1 (ar) | مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 | |
| MA41975B1 (fr) | Derives d'aminohydrothiazine fusionnee contenant du tetrahydrofurane utiles dans le traitement de la maladie d'alzheimer | |
| NZ764004A (en) | Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators | |
| PH12020500233A1 (en) | Adamantylmethylamine derivative and use thereof as pharmaceutical | |
| MD4200280T2 (ro) | Derivați de fenil-3,4-dihidroizochinolin-2(1H)-il-etan-1-onă în calitate de modulatori alosterici pozitivi ai receptorului de dopamină D1 | |
| MX2022005912A (es) | Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria. |